Delving into the Latest Updates on CS-20AT04 with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

CS 20 AT 04, CS 20AT04, CS20AT04-LN101

+ [1]

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Autoimmune cytopeniasLupus Nephritis

Inactive Indication-

Originator Organization

CORESTEMCHEMON, Inc.

Active Organization

CORESTEMCHEMON, Inc.

Inactive Organization

Hanyang University

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.
If the subjects who participated in the phase 1 clinical trial voluntarily agree to participate in this observation study, visit 1 and visit 2 will be conducted every 3 months according to the clinical trial protocol until 6 months after administration of CS20AT04 in the phase 1 clinical trial. And Visit 3 after 6 months, Visit 4
Visit 7 will be conducted every 12 months. During each visit, subjects are assessed for the efficacy and occurrence of adverse events.

Start Date29 Nov 2017

Sponsor / Collaborator

CORESTEMCHEMON, Inc.

[+1]

100 Clinical Results associated with CS-20AT04

Login to view more data

100 Translational Medicine associated with CS-20AT04

Login to view more data

100 Patents (Medical) associated with CS-20AT04

Login to view more data

100 Deals associated with CS-20AT04

Login to view more data